5/26/2020 8:39:53 AM
NeuroBo Pharma Gets Written Communication From FDA That Gemcabene Remains On Partial Clinical Hold
4/21/2020 8:32:48 AM
NeuroBo Pharma Announces Issuance Of U.S. Patent, Providing Broad Coverage Of NB-02 For Neurodegenerative Disorders
4/16/2020 4:27:52 PM
NeuroBo Pharmaceuticals Closes $7.5 Mln Registered Direct Offering
4/14/2020 9:16:58 AM
NeuroBo Pharmaceuticals Plans $7.5 Mln Registered Direct Offering
7/26/2019 6:07:18 AM
Gemphire Therapeutics And NeuroBo Pharmaceuticals To Merge
7/26/2019 6:06:47 AM
NeuroBo To Merge With Subsidiary Of Gemphire In All-stock Transaction
6/26/2019 8:15:55 AM
Gemphire Announces Top-Line Data From FPLD Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial
3/15/2019 8:04:19 AM
Gemphire Therapeutics Q4 Net Loss $3.7 Mln Or $0.26/Shr Vs Loss $6.7 Mln Or $0.63/Shr Last Year
1/3/2019 7:03:47 AM
Arcturus Therapeutics Appoints Andrew Sassine As CFO
12/3/2018 8:11:41 AM
Gemphire Therapeutics Conducts Review Of Range Of Strategic Alternatives
8/28/2018 7:01:39 AM
Arcturus Therapeutics Names Andrew Sassine Interim CFO
8/13/2018 4:04:30 PM
Gemphire Therapeutics Q2 Loss/share $0.47 Vs. Loss $0.99 Year Ago